Hide
Show all
Email this article Enhancing Non-Small Cell Lung Cancer Management with Hybrid Imaging: A Review of FDG PET/CT Applications
Abstract
Abstract:
Background: Positron emission tomography (PET) is a sensitive and specific method of molecular imaging that has become integral to oncologic studies. The use of F18-labeled glucose (FDG) in PET scans has revolutionized cancer diagnosis and management by providing valuable functional information based on increased glucose uptake and glycolysis of cancer cells. Integrated PET/CT scanners offer synergistic advantages by combining functional and anatomical data, enhancing image interpretation for more accurate staging and diagnosis while minimizing the limitations of standalone anatomical imaging.
Aim: This article reviews the role of FDG PET and FDG PET/CT in the diagnosis, staging, and treatment response assessment of lung cancer, emphasizing its clinical significance and the ongoing need for investment in PET services to meet increasing demand. The aim of our study was to search literature to understand the role of 18F-FDG PET and PET/CT in the management of lung cancer, to become familiar with recent advances and pitfalls in hybrid imaging of lung cancer.
Methods: We searched for articles in literature regarding the value of 18F-FDG PET/CT in lung cancer, describing different roles and applications of PET and PET/CT. We analyzed the data of articles published between 1994 and 2024 and summarized the information.
Results: The application of FDG PET/CT is crucial for accurate diagnosis, staging, and restaging in lung cancer, enabling the detection of metabolic abnormalities before morphological changes occur. It also plays a significant role in monitoring response to therapy, allowing timely modifications to treatment regimens and ultimately improving patient outcomes. Despite its advantages, the technology faces challenges such as cost and infrastructure requirements.
Conclusion: F18-FDG PET/CT is a valuable imaging modality for diagnosis, staging, treatment response evaluation and management of lung cancer. FDG PET/CT is cost-effective compared to other imaging modalities alone in terms of accurate staging and resectability assessment. Recent advances in hybrid imaging, such as artificial intelligence (AI) have added value for the management of lung cancer.
Keywords
Full Text:
PDFReferences
References:
Jones T, Townsend D, History and future technical innovation in positron emission tomography J. Med. Imag. 2017; 4(1), 011013
Schatka, Imke et al. “A randomized, double-blind, crossover comparison of novel continuous bed motion versus traditional bed position whole-body PET/CT imaging.” European journal of nuclear medicine and molecular imaging vol. 43,4 (2016): 711-7.
Ashraf MA, Goyal A. Fludeoxyglucose (18F) [Updated 2023 Aug 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.
Wyker A, Henderson WW. Solitary Pulmonary Nodule. [Updated 2022 Dec 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-
MacMahon, Heber et al. “Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017.” Radiology vol. 284,1 (2017): 228-243.
Gould MK, Maclean CC, e al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001; 285(7):914–924.
Nomori H, Watanabe K, et al. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer 2004; 45 (1):19–27.
Erasmus JJ, McAdams HP, et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 1998; 170(5):1369–1373
Apostolopoulos, I.D.; Papathanasiou, N.D.; Apostolopoulos, D.J.; Papandrianos, N.; Papageorgiou, E.I. Integrating Machine Learning in Clinical Practice for Characterizing the Malignancy of Solitary Pulmonary Nodules in PET/CT Screening. Diseases 2024
Erasmus JJ, Connolly JE, McAdams HP, et al. Solitary pulmonary nodules: Part I. Morphologic evaluation for differentiation of benign and malignant lesions. Radiographics 2000; 20: 43–58.
Erasmus JJ H, McAdams P, Connolly JE. Solitary Pulmonary Nodules: Part II. Evaluation of the Indeterminate Nodule; Radiographics 2000; 20: 43–58.
Grgic A, Yiksel Y, Gruschel A, et al. Risk stratification of solitary pulmonary nodules by means of PET using (18)F-fluorodeoxyglucose and SUV quantification. Eur J Nucl Med Mol Imaging. 2010;37:1087–94
Matthies A, Hickeson M, et al. Dual time point 18FFDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002; 43: 871–5.
Sathekge MM, Maes A, et al. Dual time-point FDG PET/ CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area. S Afr Med J. 2010; 100:598–601.
Kim IJ, Lee JS, et al. Double-phase 18F-FDG PET-CT for determination of pulmonary tuberculoma activity. Eur J Nucl Med Mol Imaging. 2008; 35: 808–14.
Zhang L, et al. Dual time point 18FDG-PET/CT versus single time point 18FDG-PET/CT for the differential diagnosis of pulmonary nodules: a meta-analysis. Acta Radiol. 2013; 54: 770–7.
Yi CA, Lee KS, et al. Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med. 2006; 47(3):443–450.
Kim SK, et al. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med. 2007; 48:214–20.
Feng M, et al. Retrospective analysis for the false positive diagnosis of PET-CT scan in lung cancer patients. Medicine (Baltimore) 2017;
Beyer T, Antoch G, et al. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 2003; 30(4):588–596.
Pan T, Mawlawi O, et al. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med 2005;46(9): 1481–1487.
Nii, Takeshi et al. “Evaluation of Data-Driven Respiration Gating in Continuous Bed Motion in Lung Lesions.” Journal of nuclear medicine technology vol. 51,1 (2023): 32-37
Mosmann MP, Borba MA, et al. Solitary pulmonary nodule and 18F-FDG PET/CT. Part 1: epidemiology, morphological evaluation and cancer probability. Radiol Bras. 2016 Jan/Feb; 49(1):35–42.
Mosmann MP, Borba MA, et al. Solitary pulmonary nodule and 18F-FDG PET/CT. Part 2: accuracy, cos teffectiveness, and current recommendations. Radiol Bras. 2016 Mar/Apr; 49(2):104–111.
Mylene T, et al. Update in the Evaluation of the Solitary Pulmonary Nodule; Radiographics, 2014
Frank C. Detterbeck, MD. The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Journal of Thoracic and Cardiovascular Surgery, January 2018
Antoch G, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology; 2003. 229:526–533
De Wever W, et al Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol. 2007. 17:23-32.
Lardinois D, Weder W, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003; 348:2500–2507
De Wever W, Stroobants S, et al. Integrated PET/CT in the staging of non-small cell lung cancer: technical aspects and clinical integration. Eur Respir J; 2009. 33: 201–212
Ohno, Y.; Ozawa, Y.; Koyama, H.; Yoshikawa, T.; Takenaka, D.; Nagata, H.; Ueda, T.; Ikeda, H.; Toyama, H. State of the Art MR Imaging for Lung Cancer TNM Stage Evaluation. Cancers 2023, 15, 950. https://doi.org/10.3390/cancers15030950
Cerfolio RJ, et al. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with non-small cell lung cancer. Ann Thorac Surg. 2004. 78:1017–1023
Purandare NC, et al. 18F-FDG PET/CT-directed biopsy: does it offer incremental benefit? Nucl Med Commun. 2013; 34:203–210
İntepe YS, et al. Our transthoracic biopsy practices accompanied by the imaging process: the contribution of positron emission tomography usage to accurate diagnosis. Acta Clin Belg. 2016; 71:214–220
Collins BT, et al. Initial evaluation of pulmonary abnormalities: CT-guided fine needle aspiration biopsy and fluoride-18 fluorodeoxyglucose positron emission tomography correlation. Diagn Cytopathol. 2000; 22:92–96.
Stefanidis, Konstantinos et al. “18F-FDG PET/CT anatomic and metabolic guidance in CT-guided lung biopsies.” European journal of radiology vol. 171 (2024) https://doi.org/10.1016/j.ejrad.2024.111315
Gould MK, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis; Annals of Internal Medicine, 2003. 139(11):879-92.
Kameyama, Komei et al. “New PET/CT criterion for predicting lymph node metastasis in resectable advanced (stage IB-III) lung cancer: The standard uptake values ratio of ipsilateral/contralateral hilar nodes.” Thoracic cancer vol. 13,5 (2022): 708-715. doi:10.1111/1759-7714.14302
J F Vansteenkiste, S G Stroobants, et al. FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? The Leuven Lung Cancer Group; European Journal of Nuclear Medicine, 1998; 25(11):1495-501
Birim O, et al. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg 2005;79:375-82
Billé A, et al. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothoracic Surg 2009; 36 (3):440–5.
Wang J, Welch K, et al. Negative predictive value of positron emission tomography and computed tomography for stage T1-2N0 non-small-cell lung cancer: a meta-analysis. Clin Lung Cancer 2012; 13 (2):81–89.
Zhou X, et al. Potential clinical value of PET/CT in predicting occult nodal metastasis in T1-T2N0M0 lung cancer patients staged by PET/CT. Oncotarget 2017;8:82437-45.
X. Li, et al. Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study; Radiother Oncol. 2012
Kubota K, et al. Additional value of FDG-PET to contrast enhanced-computed tomography (CT) for the diagnosis of mediastinal lymph node metastasis in non-small cell lung cancer: a Japanese multicenter clinical study Ann Nucl Med 2011
Divisi, Duilio et al. “Current role of standardized uptake valuemax-derived ratios in N2 fluorine-18 fluorodeoxyglucose positron-emission tomography non-small cell lung cancer.” Journal of thoracic disease vol. 10,1 (2018): 503-507. doi:10.21037/jtd.2017.11.137
Gao SJ, et al. Indications for invasive mediastinal staging in patients with early nonsmall cell lung cancer staged with PET-CT. Lung Cancer 2017;109:36–41.
Langen AJ, et al. The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardio Thor Surgery. 2006 29:26-29
Lee BE, et al. Advances in positron emission tomography technology have increased the need for surgical staging in non-small cell lung cancer. J Thorac Cardiovasc Surg; 2007.133:746-52.
Darling GE, et al. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial; Journal of Thoracic Oncology, 2011; Aug 6(8); 1367-72
Shen G, et al. Diagnostic value of dual time-point 18 F-FDG PET/CT versus single time-point imaging for detection of mediastinal nodal metastasis in non-small cell lung cancer patients: a meta-analysis; Acta Radiology, 2015; June 56 (6); 681-7
Peter E. Valk, Dominique Delbeke, Dale L. Bailey, David W. Townsend, Michael N. Maisey Positron Emission Tomography Clinical Practice, 2006
Ronald B. Woekman, Jr, R.Edward Coleman PET CT essentials for clinical practice, 2006
H.Jadvar, J.A.Parker Clinical PET and PET CT, 2005.
T. B. Lynch PET/CT in clinical practice, 2007
E M Marom , H P McAdams, J J Erasmus, et al. Staging non-small cell lung cancer with whole-body PET, Radiology, 1999; 212; 803-809.
R M Pieterman, J W van Putten, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000 Jul 27; 343 (4):254-61.
Saunders CA, Dussek JE, et al. Evaluation offluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999; 67: 790-797.
Stroobants S, et al. Additional value of whole-body fluorodeoxyglucose positron emission tomography in the detection of distant metastases of non-small cell lung cancer. Clin Lung Cancer 2003; 4: 242-247.
Lewis P, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994;344:1265-1266.57
MacManus MP, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:287-293
Kumar R, et al. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med 2004; 45: 2058–62.
Brady MJ, et al. Adrenal Nodules at FDG PET/CT in Patients Known to Have or Suspected of Having Lung Cancer: A Proposal for an Efficient Diagnostic Algorithm. Radiology. 2009. 250:523–530
Wu Q, et al. The utility of FDG PET/CT for the diagnosis of adrenal metastasis in lung cancer: a PRISMA-compliant meta-analysis. Nucl Med Commun 2017; 38(12):1117–1124.
Liu T, et al. Fluorine-18 deoxyglucose Positron emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer: which one is the best? A Meta-analysis. Clin Oncol (R Coll Radiol) 2010.
Qu X, et al. A meta-analysis of 18FDG-PET-CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol 2012;81(5):1007–1015.
R. Hustinx, et al. Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases ;Annals of Oncology 1998;
Cui, Yingpu et al. “The impact of deep-inspiration breath-hold total-body PET/CT imaging on thoracic 18F-FDG avid lesions compared with free-breathing.” European journal of radiology vol. 177 (2024): 111549. doi: 10.1016/j.ejrad.2024.111549
Wu Y, et al. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/ computed tomography for the detection of metastases in non-small-cell lung cancer patients. Int J Cancer 2013; 132 (2):E37–E47.
T Bury, et al. Value of FDG-PET in detecting residual or recurrent non-small cell lung cancer European Respiratory Journal 1999 14: 1376-1380;
Erasmus JJ MD, Patz EF Jr MD. Positron Emission Tomography Imaging in the Thorax; Clin Chest Med 1999; 20(4):715-724
Weber WA, Petersen V, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use; J Clin Oncol 2003
Mac Manus MP, Hicks RJ, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer; J Clin Oncol 2003
Cerfolio RJ, et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer; Annals of Thoracic Surgery; 2004
Sheikhbahaei S, Mena E, Marcus C, Wray R, Taghipour M, Subramaniam R. 18F-fluorodeoxyglucose PET/CT: therapy response assessment interpretation (Hopkins criteria) and survival outcomes in lung cancer patients. J Nucl Med 2016; 57:855–860
Kremer R, et al. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy. Ann Nucl Med 2016; 30:114–121
Moon SH, et al. Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy. Eur J Nucl Med Mol Imaging 2013; 40:1005–1013
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors Nucl Med 2009; 50:122S–150S
Dang, Shreya et al. “Evaluation of treatment response by Hopkins criteria on 18 F FDG PET-CT in patients of non-small cell lung cancer and its comparison with PERCIST response criteria.” Nuclear medicine communications vol. 44,11 (2023): 1038-1045. doi:10.1097/MNM.0000000000001756
He YQ, et al. Diagnostic efficacy of PET and PET/CT for recurrent lung cancer: a meta-analysis. Acta Radiol 2014;55:309–317
Dane B, et al. PET/CT vs. non-contrast CT alone for surveillance 1-year post lobectomy for stage I non-small-cell lung cancer. Am J Nucl Med Mol Imaging 2013; 3:408–416
Choi SH, et al. Positron emission tomography-computed tomography for postoperative surveillance in non-small cell lung cancer. Ann Thorac Surg 2011; 92:1826–1832; discussion, 1832
Sheikhbahaei S, Mena E, Yanamadala A, Solnes SRLB, Wachsmann J, Subramaniam RM The Value of FDG PET/CT in Treatment Response Assessment, Follow-Up, and Surveillance of Lung Cancer AJR 2017; 208:420–433
Paesmans M, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. Journal of Thoracic Oncology; 2010
Na F, et al. Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis. Journal of thoracic oncology; 2014;
Patz EF Jr, et al. Prognostic Value of Thoracic FDG PET Imaging After Treatment for Non-Small Cell Lung Cancer; Am J Roentgenol 2000; 174(3): 769-74
Eschmann S M, et al. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer Eur J Nucl Med Mol Imaging 2007 Apr;34(4):463-71.
L.Decoster D, et al. Complete metabolic tumor response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC) Lung cancer 2008
Liu J, et al. Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A MetaAnalysis; PLOS ONE, January 4, 2016
Lee P, et al. BW Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. Clin Lung Cancer 2012
Lee, H.; Choi, Y.-L.; Kim, H.K.; Choi, Y.S.; Kim, H.; Ahn, M.-J.; Pyo, H.R.; Choi, J.Y. Prognostic Significance of Volumetric Parameters Based on FDG PET/CT in Patients with Lung Adenocarcinoma Undergoing Curative Surgery. Cancers 2023, 15, 4380. https://doi.org/10.3390/cancers15174380
Van Tinteren H, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002; 359(9315):1388–1393.
Kubota K, et al. Impact of FDGPET findings on decisions regarding patient management strategies: a multicenter trial in patients with lung cancer and other types of cancer. Ann Nucl Med 2015; 29(5):431–441.
Gregory DL, et al. Effect of PET/CT on Management of Patients with Non–Small Cell Lung Cancer: Results of a Prospective Study with 5-Year Survival Data J Nucl Med 2012; 53:1007–1015
Boom Ting Kung, et al. The Pearl of FDG PET/CT in Preoperative Assessment of Patients with Potentially Operable Non–Small‑Cell Lung Cancer and its Clinical Impact W J Nuc Med 2020
Takeuchi S, et al. Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 2014; 41(5):906–914.
W.J. Scott, et al. Cost-effectiveness of FDG-PET for staging non–small cell lung cancer: a decision analysis Ann Thorac Surg 1998 66 (6): 1876-1883
Dietlein M, Weber K, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT result European Journal of Nuclear Medicine 2000 volume 27, pages1598–1609
Schreyogg J, et al. Cost-Effectiveness of Hybrid PET/CT for Staging of Non–Small Cell Lung Cancer Jonas J Nuc Med 2010
Andreas K. Buck, Ken Herrmann, Tom Stargardt, Tobias Dechow, Bernd Joachim Krause, Jonas Schreyögg Journal of Nuclear Medicine Technology Mar 2010, 38 (1) 6-17; DOI: 10.2967/jnmt.108.059584
Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009; 50 Suppl 1:11S-20S.
Beyer T, Townsend DW, Brun T et al. A combined PET CT scanner for clinical oncology. J NUc Med 2000; 41 :1369-1379
I Brink, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer Eur J Nuc Med Mol Imag 2004
Bradley JD, et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study JCO 2004
Azad A, et al. High impact of 18F-FDG PET on management and prognostic stratification of newly diagnosed small cell lung cancer. Mol Imaging Biol 2010;12:433–51
Fischer BM, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol 2007;18:338–45
Martucci F, G. Traglia et al. Impact of 18F-FDG PET/CT in Staging Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Frontiers of Medicine 2020
Ehab M Kamel, et al. Whole-Body 18F-FDG PET Improves the Management of Patients with Small Cell Lung Cancer J Nuc Med 2003
Yamamoto Y, et al. Early assessment of therapeutic response using FDG PET in small cell lung cancer. Mol Imaging Biol 2009; 11: 467–72.
D. Ziai T, et al.Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria Cancer Imaging 2013
Lee YJ, et al. High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res 2009;15:2426–32
Pandit N, et al. Prognostic value of [18F] FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2003; 30: 78–84.
Graabak G, Grønberg BH, Killingberg KT, Halvorsen TO, Effect of FDG PETCT for Staging and Radiotherapy Planning – a Comparison of Cohorts from Two Randomized Trials of Thoracic Radiotherapy in Limited-Stage SCLC, JTO Clinical and Research Reports (2024), doi: https:// doi.org/10.1016/j.jtocrr.2024.100688.
Ambrosini V, et al. S PET/CT imaging in different types of lung cancer: An overview Eur J Rad 2012
S.Volpi, et al. The role of positron emission tomography in the diagnosis, staging and response assessment of non-small cell lung cancer; Ann Transl Med 2018; 6(5):95
John Cuaron, et al. of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer; Frontiers in Oncology, 2013
Konishi J, et al. Mediastinal lymph node staging by FDG-PET in patients with nonsmall cell lung cancer: analysis of false-positive FDG-PET findings. Respiration 2003;70(5):500–506.
Betancourt-Cuellar SL, et al.. Pitfalls and limitations in non-small cell lung cancer staging. Semin Roentgenol 2015; 50(3):175–182.
Al-Sarraf N, et al. Lymph node staging by means of positron emission tomography is less accurate in non-small cell lung cancer patients with enlarged lymph nodes: analysis of 1,145lymph nodes. Lung Cancer 2008; 60, 62–68.
Shiraki N, et al. False-positive and true negative hilar and mediastinal lymph nodes on FDG-PET–radiological- pathological correlation. Ann.Nucl. Med. 2004 18, 23–28.
Zhang X, et al. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small- cell lung cancer. Int. J.Radiat. Oncol. Biol. Phys. 2012 83, 1558–1565.
Hoopes D.J, et al. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer 2007; 56, 229–234.
Liu, C, et al, The impact of respiratory motion on tumor quantification and delineation in static PET/CT imaging. Phys. Med. Biol.2009; 54, 7345–7362.
Vesselle H, et al. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J. Thorac. Oncol. 2008 3, 971–978.
Meirelles GS, Capobianco J, de Oliveira MA. Pitfalls and artifacts in the interpretation of oncologic PET/CT of the chest. Radiol Bras. 2017 Jan-Feb;50(1):55-59. doi: 10.1590/0100-3984.2015.0194. PMID: 28298733; PMCID: PMC5347504.
Textbook:
Branislav Eremic, Advances in Radiation Oncology in Lung Cancer, 3rd ed, 2023, Springer;
Refbacks
- There are currently no refbacks.
ISSN: 2346-8491 (online)